Cantor Fitzgerald Issues Positive Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target lifted by Cantor Fitzgerald from $590.00 to $595.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the pharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 26.40% from the stock’s current price.

VRTX has been the topic of a number of other research reports. Royal Bank Of Canada raised their price target on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, July 17th. UBS Group lifted their price target on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Canaccord Genuity Group lowered their price target on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a report on Tuesday, May 5th. Finally, Morgan Stanley upped their price objective on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Twenty-two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $560.09.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $470.72 on Tuesday. Vertex Pharmaceuticals has a 52 week low of $362.50 and a 52 week high of $533.67. The firm has a market cap of $119.47 billion, a P/E ratio of 27.92, a price-to-earnings-growth ratio of 2.15 and a beta of 0.30. The firm’s 50-day simple moving average is $471.34 and its 200 day simple moving average is $460.44.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter last year, the firm earned $4.52 earnings per share. The business’s revenue for the quarter was up 12.5% compared to the same quarter last year. As a group, equities analysts forecast that Vertex Pharmaceuticals will post 17.01 earnings per share for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 1,541 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $519.00, for a total transaction of $799,779.00. Following the sale, the executive vice president owned 11,001 shares of the company’s stock, valued at approximately $5,709,519. The trade was a 12.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total transaction of $787,485.00. Following the transaction, the executive vice president owned 45,321 shares of the company’s stock, valued at $23,793,071.79. This trade represents a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,452 shares of company stock worth $8,103,997 over the last quarter. Corporate insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bangor Savings Bank boosted its holdings in shares of Vertex Pharmaceuticals by 0.4% during the second quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock worth $2,220,000 after purchasing an additional 20 shares during the period. Earned Wealth Advisors LLC increased its stake in Vertex Pharmaceuticals by 3.3% in the 4th quarter. Earned Wealth Advisors LLC now owns 650 shares of the pharmaceutical company’s stock valued at $295,000 after buying an additional 21 shares during the period. Confluence Wealth Services Inc. increased its stake in Vertex Pharmaceuticals by 4.0% in the 4th quarter. Confluence Wealth Services Inc. now owns 545 shares of the pharmaceutical company’s stock valued at $247,000 after buying an additional 21 shares during the period. Williams Jones Wealth Management LLC. lifted its position in Vertex Pharmaceuticals by 1.9% in the 4th quarter. Williams Jones Wealth Management LLC. now owns 1,155 shares of the pharmaceutical company’s stock worth $524,000 after buying an additional 21 shares in the last quarter. Finally, Trust Point Inc. boosted its stake in shares of Vertex Pharmaceuticals by 2.7% during the 2nd quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock valued at $394,000 after buying an additional 21 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue rose 12.5% year over year to $3.33 billion, topping analysts’ $3.23 billion estimate. Growth was supported by strong demand for Vertex’s cystic fibrosis medicines, as well as continued contributions from sickle cell disease, beta thalassemia and acute pain products. Vertex raises annual revenue forecast on cystic fibrosis drugs strength
• Positive Sentiment: Vertex raised its 2026 revenue outlook to $13.1 billion-$13.2 billion, implying a $13.15 billion midpoint slightly above the $13.0 billion analyst consensus. The higher forecast reflects sustained cystic fibrosis sales momentum. Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance
• Positive Sentiment: The pending acquisition of Crinetics would expand Vertex into rare endocrine diseases through Paltusotine and create a fifth commercial pillar, potentially diversifying growth beyond cystic fibrosis. Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Adjusted EPS increased to $4.73 from $4.52 a year earlier and was essentially in line with the $4.74 consensus in some reports, while other estimates showed a slightly wider miss at $4.79. This modest earnings shortfall limited the positive reaction to the revenue beat. Vertex Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: Investors appear concerned about the approximately $10 billion Crinetics purchase, including its execution risk and the need to absorb a sizable acquisition while Vertex continues investing in its pipeline. Those concerns, combined with the EPS miss, contributed to the stock’s decline despite stronger sales guidance. Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.